After finishing at $12.95 in the prior trading day, Amicus Therapeutics Inc (NASDAQ: FOLD) closed at $12.82, down -1.00%. In other words, the price has decreased by -$0.13 from its previous closing price. On the day, 3997214 shares were traded. FOLD stock price reached its highest trading level at $13.18 during the session, while it also had its lowest trading level at $12.52.
Ratios:
Our goal is to gain a better understanding of FOLD by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.52 and its Current Ratio is at 2.88. In the meantime, Its Debt-to-Equity ratio is 2.78 whereas as Long-Term Debt/Eq ratio is at 2.73.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Morgan Stanley on December 19, 2023, Upgraded its rating to Overweight and sets its target price to $20 from $15 previously.
On September 09, 2022, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $14.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 15 when Crowley John F sold 31,614 shares for $13.81 per share. The transaction valued at 436,551 led to the insider holds 697,628 shares of the business.
Clark David Michael sold 4,427 shares of FOLD for $61,978 on Feb 15. The Chief People Officer now owns 253,664 shares after completing the transaction at $14.00 per share. On Feb 15, another insider, Campbell Bradley L, who serves as the President and CEO of the company, sold 4,167 shares for $14.00 each. As a result, the insider received 58,338 and left with 871,219 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FOLD now has a Market Capitalization of 3.96B and an Enterprise Value of 3.93B. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.41 while its Price-to-Book (P/B) ratio in mrq is 23.50. Its current Enterprise Value per Revenue stands at 10.57 whereas that against EBITDA is -29.56.
Stock Price History:
Over the past 52 weeks, FOLD has reached a high of $14.57, while it has fallen to a 52-week low of $9.70. The 50-Day Moving Average of the stock is 13.23, while the 200-Day Moving Average is calculated to be 12.33.
Shares Statistics:
The stock has traded on average 3.26M shares per day over the past 3-months and 3.79M shares per day over the last 10 days, according to various share statistics. A total of 293.59M shares are outstanding, with a floating share count of 284.43M. Insiders hold about 3.01% of the company’s shares, while institutions hold 107.38% stake in the company. Shares short for FOLD as of Feb 15, 2024 were 26.78M with a Short Ratio of 8.21, compared to 25.06M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 9.13% and a Short% of Float of 9.17%.
Earnings Estimates
Its stock is currently analyzed by 7 different market analysts. On average, analysts expect EPS of -$0.05 for the current quarter, with a high estimate of $0 and a low estimate of -$0.1, while EPS last year was -$0.18. The consensus estimate for the next quarter is $0, with high estimates of $0.04 and low estimates of -$0.02.
Analysts are recommending an EPS of between $0.31 and -$0.08 for the fiscal current year, implying an average EPS of $0.07. EPS for the following year is $0.44, with 9 analysts recommending between $0.99 and $0.17.
Revenue Estimates
9 analysts predict $113.94M in revenue for the current quarter. It ranges from a high estimate of $119.7M to a low estimate of $109.2M. As of the current estimate, Amicus Therapeutics Inc’s year-ago sales were $83.08M, an estimated increase of 37.10% from the year-ago figure. For the next quarter, 9 analysts are estimating revenue of $126.55M, an increase of 33.90% less than the figure of $37.10% in the same quarter last year. There is a high estimate of $128.8M for the next quarter, whereas the lowest estimate is $124.85M.
A total of 11 analysts have provided revenue estimates for FOLD’s current fiscal year. The highest revenue estimate was $547.4M, while the lowest revenue estimate was $511.09M, resulting in an average revenue estimate of $531.37M. In the same quarter a year ago, actual revenue was $399.36M, up 33.10% from the average estimate. Based on 10 analysts’ estimates, the company’s revenue will be $691.68M in the next fiscal year. The high estimate is $821.05M and the low estimate is $619.63M. The average revenue growth estimate for next year is up 30.20% from the average revenue estimate for this year.
